NPS Buys Back Rights to Gattex From Takeda to Spur Sales

NPS Pharmaceuticals Inc., a maker of rare-disease drugs, rose the most in five months after the company regained worldwide marketing and development rights to its therapy Gattex from partner Takeda Pharmaceutical Co.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.